GW up 51% on Sativex trial data

GW Pharmaceuticals, the group that is licensed to use cannabis in its treatments, announced yesterday that its Sativex drug had produced positive trial data and that the treatment is set to be submitted for regulatory approval.

GW's shares closed the day up 51 per cent after multiple sclerosis patients using Sativex experienced reduced spasticity, compared to when using other treatments. GW said that it would file Sativex for final approval from next month, after which the group will start marketing the drug.